Is Epizyme Incorporated (NASDAQ:EPZM) a Buy? The Stock Reported Less Sellers

January 18, 2018 - By Migdalia James

 Is Epizyme Incorporated (NASDAQ:EPZM) a Buy? The Stock Reported Less Sellers

Investors sentiment decreased to 1.46 in Q3 2017. Its down 0.47, from 1.93 in 2017Q2. It fall, as 15 investors sold Epizyme, Inc. shares while 22 reduced holdings. 13 funds opened positions while 41 raised stakes. 58.04 million shares or 22.28% more from 47.46 million shares in 2017Q2 were reported.
State Board Of Administration Of Florida Retirement reported 19,542 shares. Gotham Asset Management Limited Co invested 0.01% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM). Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Epizyme, Inc. (NASDAQ:EPZM) for 988 shares. Bnp Paribas Arbitrage reported 0% stake. Credit Suisse Ag accumulated 64,789 shares or 0% of the stock. Secor L P reported 69,876 shares or 0.13% of all its holdings. California State Teachers Retirement Sys invested in 66,249 shares or 0% of the stock. Moreover, Federated Invsts Pa has 0% invested in Epizyme, Inc. (NASDAQ:EPZM) for 43,020 shares. Nea Mgmt Limited Liability Corp stated it has 4.31% in Epizyme, Inc. (NASDAQ:EPZM). Rhumbline Advisers owns 50,620 shares. Point72 Asset Mngmt L P accumulated 923,400 shares or 0.08% of the stock. Aqr Cap Mngmt Ltd Com has invested 0% in Epizyme, Inc. (NASDAQ:EPZM). Geode Capital Management Limited Liability Corp has 0% invested in Epizyme, Inc. (NASDAQ:EPZM) for 470,541 shares. Tiaa Cref Invest Mgmt Ltd Liability Com holds 0% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM) for 110,012 shares. Fmr Lc holds 0.02% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM) for 10.17M shares.

Since August 24, 2017, it had 1 buying transaction, and 3 insider sales for $2.32 million activity. Ho Peter Tai-Ching sold 15,000 shares worth $246,591.

The stock of Epizyme Incorporated (NASDAQ:EPZM) registered a decrease of 1.61% in short interest. EPZM’s total short interest was 5.66 million shares in January as published by FINRA. Its down 1.61% from 5.75M shares, reported previously. With 468,200 shares average volume, it will take short sellers 12 days to cover their EPZM’s short positions. The short interest to Epizyme Incorporated’s float is 15.71%.

The stock increased 0.50% or $0.07 during the last trading session, reaching $15. About 212,964 shares traded. Epizyme, Inc. (NASDAQ:EPZM) has risen 91.85% since January 18, 2017 and is uptrending. It has outperformed by 75.15% the S&P500.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has market cap of $1.04 billion. The Company’s product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma ; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It currently has negative earnings. The firm is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL.

Epizyme, Inc. (NASDAQ:EPZM) Ratings Coverage

Among 12 analysts covering Epizyme (NASDAQ:EPZM), 11 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Epizyme had 29 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, June 12 by RBC Capital Markets. SunTrust maintained the shares of EPZM in report on Friday, October 27 with “Buy” rating. As per Wednesday, June 7, the company rating was maintained by H.C. Wainwright. The stock has “Outperform” rating by RBC Capital Markets on Monday, September 28. The stock of Epizyme, Inc. (NASDAQ:EPZM) has “Buy” rating given on Tuesday, May 10 by Mizuho. The company was maintained on Wednesday, June 7 by Cowen & Co. The stock has “Buy” rating by Mizuho on Thursday, August 6. As per Thursday, November 2, the company rating was maintained by H.C. Wainwright. As per Thursday, June 15, the company rating was maintained by Leerink Swann. The company was downgraded on Thursday, November 2 by RBC Capital Markets.

More news for Epizyme, Inc. (NASDAQ:EPZM) were recently published by: Benzinga.com, which released: “Morgan Stanley: Epizyme Has ‘Blockbuster’ Cancer Drug In The Making” on January 10, 2018. Benzinga.com‘s article titled: “ICYMI: Epizyme, MoviePass, And A Bull Call On Novavax” and published on January 10, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.